Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Introduction

• Org Study ID: Pro00107408
• NTC ID: NCT04919122
• Lead Sponsor Name: Duke University
• Status: RECRUITING

Conditions

• Renal Cell Carcinoma

Brief Summary

ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.

Eligibility Criteria

Inclusion Criteria:

* Age 19 or over at time of informed consent.
* Diagnosis of metastatic renal cell cancer (mRCC) with less than or equal to (≤) 6 weeks of first-line systemic therapy for mRCC.

1. Prior surgery and radiation therapy are permitted.
2. Prior neoadjuvant and adjuvant therapy for non-metastatic renal cell carcinoma are permitted.
3. Patients currently not on therapy and being observed are permitted.
* Evidence of signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
* Ability to comply with completion of PROs

Exclusion Criteria:

* Patients being treated for metastatic solid tumors other than mRCC are excluded. Non-cytotoxic oral agents for adjuvant or maintenance therapy of other cancers are permitted.
* Patients who are not intending to undergo follow up care at a study site within PCORnet